en · de · es · fr · pt
glossary-desk.peptides6155.com › Info › Thymosin Beta-4 Fragment Overview — What the Evidence Shows

Thymosin Beta-4 Fragment Overview — What the Evidence Shows

By Editorial Desk · published 2025-07-25 · last reviewed 2025-08-26 · Info

If you have been reading about actin binding and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2025-08-26. Where a claim depends on a specific study, the study is described rather than over-claimed.

Thymosin Beta-4 Fragment Overview

Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.

The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.

Thymosin Beta-4 Fragment Identity

No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.

TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.

Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.

Tb-500 at a glance

PropertyValueNotes
AppearanceWhite to off-white powderLyophilized solid as supplied
Water solubilitySolubleDissolves in aqueous media
Typical storage temperature-20 °CDry powder, desiccated, protected from light
Typical analytical methodRP-HPLC with mass spectrometryPurity from peak area; mass for identity
Common synonymsTβ4 fragment; thymosin beta-4 fragmentNaming varies by supplier and catalogue

Research Framing and Evidence Base

Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.

Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.

Related pages on this site

Storage, Handling, and Analytical Checks

Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.

Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.

Supporting material

==== Electrophoresis ==== Capillary electrophoresis (CE) and microcapillary gel electrophoresis (μCGE) are well-recognized microchip electrophoresis (MCE) methods that can provide numerous analytical advantages including high resolution, high sensitivity, and effective coupling to mass spectrometry (MS). Microchip electrophoresis can be applied generally as a method for high-throughput screening processes that help discover and evaluate drugs. Using MCE, specifically CE, microcapillary gel electrophoresis (μCGE) devices are created to perform high-number DNA sample processing, which makes it a good candidate for DNA analysis. μCGE devices are also practical for separation purposes because they use online separation, characterization, encapsulation, and selection of differing analytes originating from a composite sample. All of these advantages of MCE methods translate to microfluidic devices. The reason MCE methods are coupled to droplet-based microfluidic devices is because of the ability to analyze samples on the nanoliter scale. Using MCE methods on a small scale reduces cost and reagent use. Similarly to HPLC, fluorescence based detection techniques are used for capillary electrophoresis, which make these methods practical and can be applied to fields such as biotechnology, analytical chemistry, and drug development. These MCE and other electrophoresis based methods began to develop once capillary electrophoresis gained popularity in the 1980s and gained even more attention in the early 1990s, as it was reviewed nearly 80 times by the year 1992.

North Central West Virginia Airport, US, IATA code Sorani, Central Kurdish branch language, ISO 639-3 code The Cracow Klezmer Band, a Polish band Crazy Ken Band, a Japanese band CKB Banka, a bank in Montenegro CKB (gene), a gene that encodes brain-type creatine kinase Chung Khiaw Bank, a Singapore bank with branches and subsidiaries in Malaysia and Hong Kong CK Birla Group, Indian conglomerate C. K. Birla, Indian businessman, founder of the group

The first Polynesian settlers arrived in Tahiti around 400 AD by way of Samoan navigators and settlers via the Cook Islands. Over the period of half a century there was much inter-island relations with trade, marriages and Polynesian expansion with the Islands of Hawaii and through to Rapa Nui. The original Tahitians cleared land for cultivation on the fertile volcanic soils and built fishing canoes. The tools of the Tahitians when first discovered were made of stone, bone, shell or wood. The Tahitians were divided into three major classes (or castes): ariʼi, raʼatira and manahune. Ariʼi were relatively few in number while manahune constituted the bulk of population and included some members who played essential roles in the society. It is estimated that by the first contact with Europeans in 1767 the population of Tahiti was most probably around 110,000 or even reached 180,000. Other Society Islands held probably 15,000-20,000 people. Tahitians divided the day into the periods of daylight (ao) and darkness (pō). There was also a concept of irrational fear called mehameha, translated as uncanny feelings. The healers, familiar with herbal remedies, were called taʼata rāʼau or taʼata rapaʼau. In the 19th century Tahitians added the European medicine to their practice. The most famous Tahitian healer Tiurai, of ariʼi, died at age 83 during the influenza outbreak on Tahiti in 1918.

== External links == Jane Higdon, "Vitamin A", Micronutrient Information Center, Linus Pauling Institute, Oregon State University NIH Office of Dietary Supplements – Vitamin A Vitamin A Deficiency at the Merck Manual of Diagnosis and Therapy

Four days after obtaining the "authority of a sovereign state" in 1955, West Germany joined NATO. The UK and the USA retained an especially strong presence in West Germany, acting as a deterrent in case of a Soviet invasion. In 1976, West Germany became one of the founding nations of the Group of Six (G6). In 1973, West Germany—home to roughly 1.26% of the world's population—featured the world's fourth-highest GDP of 814,796 million compared to East Germany's 129,969 million, together combining for 944,755 million and accounting for 5.9% of the world total. In 1987, the FRG held a 7.4% share of total world production.

Sources: en.wikipedia.org

Notes from published material

=== Development of iron metallurgy === Iron is one of the elements undoubtedly known to the ancient world. It has been worked, or wrought, for millennia. However, iron artefacts of great age are much rarer than objects made of gold or silver due to the ease with which iron corrodes. The technology developed slowly, and even after the discovery of smelting it took many centuries for iron to replace bronze as the metal of choice for tools and weapons.

=== Gastrointestinal bleeding === The ratio is useful for the diagnosis of bleeding from the gastrointestinal (GI) tract in patients who do not present with overt vomiting of blood. In children, a BUN:Cr ratio of 30 or greater has a sensitivity of 68.8% and a specificity of 98% for upper gastrointestinal bleeding. A common assumption is that the ratio is elevated because of amino acid digestion, since blood (excluding water) consists largely of the protein hemoglobin and is broken down by digestive enzymes of the upper GI tract into amino acids, which are then reabsorbed in the GI tract and broken down into urea. However, elevated BUN:Cr ratios are not observed when other high protein loads (e.g., steak) are consumed. Renal hypoperfusion secondary to the blood lost from the GI bleed has been postulated to explain the elevated BUN:Cr ratio. However, other research has found that renal hypoperfusion cannot fully explain the elevation.

== Diseases and pests == Stem rot disease is caused by the fungus Agroathelia rolfsii (aka Sclerotium rolfsii or Athelia rolfsii), which is one of the most important pathogens causing tuber and stem rot and up to 60% loss in Jerusalem artichoke yield. Growing resistant varieties is an important method of controlling Agroathelia rolfsii.

In 2010, the company and Sanofi-Aventis created an outsourcing partnership, which, at the time was considered the largest between a contract research organization and a pharmaceutical company. Covance also acquired sites from Sanofi-Aventis in Porcheville, France and Alnwick, United Kingdom. In 2014, the company acquired Medaxial, a London-based value communication consultancy. In February 2015, Labcorp acquired Covance for $6.1 billion in cash and stock. In 2016, the company entered into a strategic alliance with Global Specimen Solutions, in which the company offered GSS products GlobalCODE and snapTRACK to its clients. In December 2017, Covance acquired the company. In September 2017, the company acquired Chiltern, a specialty contract research organization, for $1.2 billion in cash. In June 2018, the company acquired Sciformix Corporation, a scientific process outsourcing company focused on pharmacovigilance and regulatory issues for biopharmaceutical and medical devices clients. In August 2018, Covance Food Solutions was sold to Eurofins Scientific for $670 million. In June 2019, the company acquired the nonclinical contract research services business of Envigo (now Inotiv), which acquired the research products business of the company. In the first quarter of 2019, the company spent $47 million to acquire MI Bioresearch, a provider of preclinical capabilities in cell and gene therapy and oncology testing, and Regulatory and Clinical Research Institute (RCRI), a device-focused contract research organization.

Sources: en.wikipedia.org

Background from the literature

The bill passed by a bipartisan vote and prohibits pharmacy benefit managers from sending customers to pharmacies they have a financial interest in and from charging health insurance plans a higher price for a drug than what the pharmacy benefit managers pay the pharmacy.

For the next 30 years, Gladstone and Liberalism were synonymous. William Gladstone served as prime minister four times (1868–74, 1880–85, 1886, and 1892–94). His financial policies, based on the notion of balanced budgets, low taxes and laissez-faire, were suited to a developing capitalist society, but they could not respond effectively as economic and social conditions changed. Called the "Grand Old Man" later in life, Gladstone was always a dynamic popular orator who appealed strongly to the working class and to the lower middle class. Deeply religious, Gladstone brought a new moral tone to politics, with his evangelical sensibility and his opposition to aristocracy. His moralism often angered his upper-class opponents (including Queen Victoria), and his heavy-handed control split the Liberal Party. In foreign policy, Gladstone was in general against foreign entanglements, but he did not resist the realities of imperialism. For example, he ordered the occupation of Egypt by British forces in the 1882 Anglo-Egyptian War. His goal was to create a European order based on co-operation rather than conflict and on mutual trust instead of rivalry and suspicion; the rule of law was to supplant the reign of force and self-interest. This Gladstonian concept of a harmonious Concert of Europe was opposed to and ultimately defeated by a Bismarckian system of manipulated alliances and antagonisms. As prime minister from 1868 to 1874, Gladstone headed a Liberal Party which was a coalition of Peelites like himself, Whigs and Radicals.

== Career and research == After graduating, Hopkins then taught physiology and toxicology at Guy's Hospital from 1894 to 1898. In 1898, while attending a meeting of the Physiological Society, he was invited by Sir Michael Foster to join the Physiological Laboratory in Cambridge to investigate the chemical aspects of physiology. Biochemistry was not, at that time, recognised as a separate branch of science. He was a lecturer in chemical physiology at Emmanuel College, Cambridge in March 1900, when he received the academic rank Master of Arts (MA) honoris causa. He earned a doctorate in physiology (D.Sc.) from the University of London in July 1902, and at the same time was given a readership in biochemistry at Trinity College. While at Cambridge he was initiated into Freemasonry. In 1910 he became a Fellow of Trinity College, and an Honorary Fellow of Emmanuel College. In 1914 he was elected to the Chair of Biochemistry at Cambridge University, thus becoming the first Professor in that discipline at Cambridge. His Cambridge students included neurochemistry pioneer Judah Hirsch Quastel and pioneer embryologist Joseph Needham. Hopkins had for a long time studied how cells obtain energy via a complex metabolic process of oxidation and reduction reactions. His study in 1907 with Sir Walter Morley Fletcher of the connection between lactic acid and muscle contraction was one of the central achievements of his work on the biochemistry of the cell. He and Fletcher showed that oxygen depletion causes an accumulation of lactic acid in the muscle.

Sources: en.wikipedia.org

Frequently asked questions

What is TB-500?

TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.

How does it differ from full thymosin beta-4?

The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.

Is human evidence available?

Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.

Is TB-500 the same as thymosin beta-4?

Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.

Network